
People of colour: there's a bias in how pictures are used to depict disease in global health publications
We started to realise how photographs can send the wrong message when we were approached, as a group of infectious disease specialists, to develop a presentation on resistance to antibiotics. Our audience was a clinical group in east Africa.
The global health organisation that asked us to do this wanted to use its own branding on our teaching slides. But when we got our slides back, we found the organisation had used an image of black African women in traditional outfits looking like they were dancing and holding white candles. Confused, we pointed out that the photograph wasn't relevant to our work. We were told this was standard imaging verified for use in global health within the organisation.
One of our colleagues pointed out that the image was of women in Nigeria going to church. We wondered whether an image of nuns would have been used for a health presentation to a European audience.
After speaking about this experience with colleagues from different ethnic backgrounds, we decided to look at how people are represented in global health literature and publications about antibiotic resistance and vaccination.
What we found was evidence of power imbalances in race, geography and gender. Through the choice of images in publications, women and children of colour in low income countries were treated with less dignity and respect than those in high income countries. Evidence of consent for using intrusive and unnecessary images was absent. And often the images were used out of context.
We then tried to suggest some guidelines for using images more appropriately.
The first step was to find out whether the use of photographs of people in global health was subject to any ethical standards or guides. We found guidelines from Photographers Without Borders, European Non-governmental Confederation for Relief and Development (CONCORD), Code of Conduct on Images and Messages, and the National Press Photographers Association – but no standards specific to health. This is a critical gap.
While the concept of patient confidentiality is closely guarded in many countries, global health seems to slip through the net of regulation or guidelines. For instance, taking candid photos of patients, especially in healthcare settings, is strictly prohibited for research- and healthcare-related activities. Any such practices must be subject to strict ethical review processes and informed consent.
But the regulations are not applied equitably or universally.
Our evaluation of images of people used in global health looked at four aspects: relevance, integrity, consent and representation. We included in the review photographs of people that had been featured in publicly available documents from global health actors published between 2015 and 2022.
In over 118 reports from 14 global health actors, there were 1,115 images. Of these, 859 included people. We found an over representation of people, including women and children of colour, in the images used. Two out of every three images were of people of colour, and for children this increased to nine out of every 10 images. Images that depicted people of colour were predominantly representing countries in the global south and were candid images of real life and often in healthcare settings. There were images of adults and children receiving healthcare, some in distressed situations or while receiving medical examinations. In contrast, images used from the global north depicted sterile settings, were often staged, and included actors.
Overall, we found representations of people of colour and women and children from the global south to be more likely to be represented in ways that were inequitable and unethical. The persistent use of intrusive images was of particular concern.
In the field of infectious diseases, global health and tropical medicine emerged as disciplines to protect white colonisers from the tropical climates and communicable diseases of the countries being colonised. Thus, historically, imagery in global health has also suffered from telling a story of diseases, war, famine, and poverty, to generate sympathy or funds for research and development.
Photographs are powerful in the imprint they leave in the collective psyche. There are ethical responsibilities in how we capture, contextualise and distribute photographs of people. Global health photography has a different purpose from journalism. But the lack of ethical standards or guidelines has blurred the distinction.
For example, recently the monkeypox outbreak in the north was visualised using black skin. And images of child victims of war and rape captured by Médecins Sans Frontières found their way into stock image libraries for sale.
Current practices in use of photographs of people in global health run the risk of perpetuating attitudes that are rooted in colonialism and reinforcing racial stereotypes. They can reinforce 'white saviour' narratives, shaming, cultural appropriation and cultural exoticism.
We have developed a framework to assist those who wish to visually represent people in global health within the boundaries of accepted standards. The aim is to:
assure the relevance of the images depicted
uphold the right to dignity and privacy of subjects
provide a mechanism for transparent consent in participation of subjects in the photograph and its subsequent use
ensure equitable and accurate representation of individuals and serve to counter stereotypes.
Recognising how powerful and necessary imagery is, we urge all readers to view this framework and join the conversation to find a more ethical and equitable representation of health and illness that does not discriminate against people according to race, gender, geographic, cultural identity and age.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Esmita Charani, University of Liverpool and Marc Mendelson, University of Cape Town
Read more:
Train derailments get more headlines, but truck crashes involving hazardous chemicals are more frequent and deadly in US
How queuing leads to city centre violence and what our research says about preventing night-time brawls
Ghana wants fewer polluting old cars on the road. But it's going about it the wrong way
Esmita Charani receives funding from Wellcome Trust, the Academy of Medical Sciences Hamied Foundation Fellowship, and the National Institute for Health Research UK. She has consulted on educational material related to antibiotic resistance for Pfizer and Biomerieux.
Marc Mendelson receives funding from The Wellcome Trust.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Concord Technologies Introduces Direct Secure Messaging Within its Concord Connect™ Platform to Transform Healthcare Data Exchange
Integration of Direct Secure Messaging and Intelligent Document Processing benefits healthcare organizations with faster access to structured data to support care delivery and interoperability SEATTLE, August 12, 2025--(BUSINESS WIRE)--Concord Technologies ("Concord"), a leader in Secure Document Exchange, Intelligent Document Processing, and Interoperability solutions, today announced the upcoming launch of Direct Secure Messaging (DSM) within its Concord Connect™ platform, available Fall 2025. This enhancement marks a significant step forward in enabling healthcare organizations to modernize how patient information is received, processed, and integrated across systems. Healthcare teams face persistent challenges in managing patient data during transitions of care and care coordination. Information often arrives from disparate systems and in both structured and unstructured formats, making timely, secure, and compliant data exchange difficult. DSM is a secure transport protocol that supports the exchange of a wide range of healthcare-related information. It is built on the widely adopted Direct Standard® and enables the secure, encrypted exchange of clinical information between trusted healthcare entities. With the addition of DSM, Concord Connect™ will support secure delivery of clinical records via a DSM address alongside Digital Fax. Using Concord's Practical AI™, these incoming documents are then indexed into appropriate queues where key pieces of patient data—whether structured or unstructured—are extracted and analyzed for intelligent workflow automation and insertion into systems of record. This process, known as Straight-Through Processing, simplifies intake workflows, accelerates integration with downstream technologies, and minimizes delays in the triage and processing of critical patient information. "At this year's DirectTrust® Annual Conference, it was exciting to see our vision for secure, interoperable data exchange validated," noted Chris Larkin, Chief Technology Officer of Concord. "Concord's ability to intelligently receive and process both structured and unstructured data addresses one of healthcare's most persistent challenges: fragmented intake workflows. By integrating multiple modalities like Digital Fax and Direct Secure Messaging into a single platform, we're enabling providers to triage and route patient information faster than ever before. The enthusiastic response from industry leaders confirms we're solving real problems—and we're just getting started." "Our vision for Straight-Through Processing is grounded in addressing the critical challenges faced by healthcare organizations," said William Cavanaugh, Chief Executive Officer of Concord. "Concord Connect is a powerful example of that vision in action—bringing together structured and unstructured data into a single, intelligent workflow. By streamlining the sharing and processing of patient data, and enabling Straight-Through Processing, we're helping providers accelerate care delivery and reduce administrative burden, all while maintaining the highest standards of security and compliance." About Concord Technologies Concord Technologies is a leading provider of Secure Document Exchange, Intelligent Document Processing, and Interoperability solutions to healthcare providers, payers, and other highly regulated businesses. For more than 20 years, billions of sensitive records containing valuable patient information have been reliably, accurately, and securely sent and received across Concord's digital health network, and today, the company processes more than 4 billion pages of protected data each year. The company is also recognized for its best-in-class development of new artificial intelligence technologies, including Concord's Practical AI™ approach to solving the most pervasive administrative challenges in the healthcare industry and for its industry-leading applications that help its customers grow and manage their business. View source version on Contacts For more information about Concord Technologies, contact:Dan Conley, PresidentBeacon Communicationscconley@ Julie Freguia, Chief Marketing OfficerConcord Technologiesjfreguia@


Business Wire
2 hours ago
- Business Wire
Concord Technologies Introduces Direct Secure Messaging Within its Concord Connect™ Platform to Transform Healthcare Data Exchange
SEATTLE--(BUSINESS WIRE)--Concord Technologies ('Concord'), a leader in Secure Document Exchange, Intelligent Document Processing, and Interoperability solutions, today announced the upcoming launch of Direct Secure Messaging (DSM) within its Concord Connect™ platform, available Fall 2025. This enhancement marks a significant step forward in enabling healthcare organizations to modernize how patient information is received, processed, and integrated across systems. Healthcare teams face persistent challenges in managing patient data during transitions of care and care coordination. Information often arrives from disparate systems and in both structured and unstructured formats, making timely, secure, and compliant data exchange difficult. DSM is a secure transport protocol that supports the exchange of a wide range of healthcare-related information. It is built on the widely adopted Direct Standard® and enables the secure, encrypted exchange of clinical information between trusted healthcare entities. With the addition of DSM, Concord Connect™ will support secure delivery of clinical records via a DSM address alongside Digital Fax. Using Concord's Practical AI™, these incoming documents are then indexed into appropriate queues where key pieces of patient data—whether structured or unstructured—are extracted and analyzed for intelligent workflow automation and insertion into systems of record. This process, known as Straight-Through Processing, simplifies intake workflows, accelerates integration with downstream technologies, and minimizes delays in the triage and processing of critical patient information. 'At this year's DirectTrust® Annual Conference, it was exciting to see our vision for secure, interoperable data exchange validated,' noted Chris Larkin, Chief Technology Officer of Concord. 'Concord's ability to intelligently receive and process both structured and unstructured data addresses one of healthcare's most persistent challenges: fragmented intake workflows. By integrating multiple modalities like Digital Fax and Direct Secure Messaging into a single platform, we're enabling providers to triage and route patient information faster than ever before. The enthusiastic response from industry leaders confirms we're solving real problems—and we're just getting started." "Our vision for Straight-Through Processing is grounded in addressing the critical challenges faced by healthcare organizations,' said William Cavanaugh, Chief Executive Officer of Concord. 'Concord Connect is a powerful example of that vision in action—bringing together structured and unstructured data into a single, intelligent workflow. By streamlining the sharing and processing of patient data, and enabling Straight-Through Processing, we're helping providers accelerate care delivery and reduce administrative burden, all while maintaining the highest standards of security and compliance." About Concord Technologies Concord Technologies is a leading provider of Secure Document Exchange, Intelligent Document Processing, and Interoperability solutions to healthcare providers, payers, and other highly regulated businesses. For more than 20 years, billions of sensitive records containing valuable patient information have been reliably, accurately, and securely sent and received across Concord's digital health network, and today, the company processes more than 4 billion pages of protected data each year. The company is also recognized for its best-in-class development of new artificial intelligence technologies, including Concord's Practical AI™ approach to solving the most pervasive administrative challenges in the healthcare industry and for its industry-leading applications that help its customers grow and manage their business.


Business Upturn
a day ago
- Business Upturn
Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients
Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) — Booking Health , a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients . The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments. Cervical Cancer Immunotherapy is redefining how doctors treat women diagnosed with stage 4 cervical cancer – offering hope where traditional treatments often fall short. According to global cancer statistics provided by the World Health Organization, cervical cancer is still ranking as the fourth most frequently diagnosed cancer among women worldwide, with over 350,000 deaths reported in 2022 alone. Therefore, the need for more effective therapies is urgent. Chemotherapy and radiation therapy remain standard for locally advanced and metastatic cervical cancer. However, they often come with harsh side effects and limited long-term benefit – especially in recurrent or PD-L1-positive cases. This is where immunotherapy is beginning to transform the way we treat cervical cancer. By training the immune system to recognize and destroy cancer cells, this innovative approach is extending survival, improving quality of life, and reshaping the future of gynecologic oncology, according to the American Cancer Society. Leading the way in connecting patients with advanced treatment abroad is Booking Health, a global medical coordination platform that offers access to advanced cervical cancer treatment in the best European clinics. Why Is Stage 4 Cervical Cancer So Hard to Treat? Stage 4 cervical cancer is difficult to treat because it involves metastatic disease, where cancer has spread beyond the pelvis to distant organs, making it less responsive to traditional therapies such as chemotherapy and radiation. In many cases, the disease becomes persistent or recurrent, with fewer effective treatment options available, as reported by the National Cancer Institute. Types of Advanced Cervical Cancer Understanding the different stages helps clarify why some cases are more complex than others: Term Definition Treatment Challenge Locally advanced cervical cancer Cancer has spread beyond the cervix to nearby tissues (e.g., vagina, parametria) but not to distant organs Often treated with chemoradiation, but recurrence risk remains Recurrent cervical cancer Cancer returns after a period of remission May resist previously used therapies and require new approaches Metastatic cervical cancer Cancer spreads to distant organs like lungs, liver, or bones Hard to target; systemic therapies often have limited success Most Common Cervical Cancer Types Squamous cell carcinoma – accounts for 80-90% of cases; originates in the ectocervix Adenocarcinoma – about 10-20% of cases; arises from glandular cells in the endocervix Adenosquamous carcinoma – a rarer subtype with mixed features As reported by Cancer Research UK, each type may behave differently in terms of spread, immune response, and treatment sensitivity. Limitations of Traditional Treatments Standard treatments for advanced cervical cancer include: Chemotherapy: Often platinum-based; effectiveness diminishes over time; Radiation therapy: Can control local disease but may not impact distant metastases; Systemic therapies: Cause significant side effects, with limited survival benefit in persistent cervical cancer. Moreover, the American Cancer Society reports that patients with persistent or metastatic disease often experience poor outcomes, with 5-year survival rates below 20% in stage 4 cases. As such, gynecologic oncology experts have increasingly turned to immunotherapy to improve response rates and extend survival. What Is Immunotherapy and How Does It Work for Cervical Cancer? Immunotherapy for cervical cancer stimulates the body's own immune system to recognize and destroy cancer cells by targeting specific immune pathways. This approach is especially useful for patients with PD-L1–positive, recurrent, or metastatic cervical cancer who may not respond well to conventional treatments. Approach Description Relevance to Cervical Cancer Immune checkpoint inhibitors Block proteins (PD-1, PD-L1) that prevent immune cells from attacking cancer Reactivates exhausted T cells to fight cervical cancer cells Monoclonal antibodies Lab-made antibodies designed to target specific tumor markers Some bind PD-L1 or deliver cytotoxic agents directly to tumor cells Cancer vaccines Stimulate immune response to HPV or tumor-associated antigens Promote lasting T cell activation and memory Adoptive T cell therapy Infuse engineered T cells that can attack tumor cells Under investigation for recurrent cervical cancer The PD-1/PD-L1 Pathway PD-1 is a receptor on T cells that regulates immune response PD-L1 is often overexpressed on cervical cancer cells When PD-L1 binds to PD-1, it 'switches off' the immune attack Checkpoint inhibitors block this interaction – reactivating T cells to destroy cancer cells Why It Matters Many cervical tumors exhibit high PD-L1 expression, making them ideal candidates for immunotherapy. Successful treatment leads to greater T cell infiltration into tumors, enhancing immune surveillance. Patients often experience improved immune response and more durable control of the disease than with chemotherapy alone. This therapeutic shift reflects a broader move toward personalized medicine in gynecologic oncology, targeting tumor-infiltrating lymphocytes and immune checkpoints rather than relying solely on cytotoxic drugs. Findings from the Latest Clinical Trials Recent phase III clinical trials have shown that combining immunotherapy with standard chemotherapy – or using it as a second-line option – can significantly extend survival and delay disease progression in patients with recurrent or metastatic cervical cancer. These studies demonstrate that there has occurred a major shift in how advanced cervical cancer is treated, providing hope to patients who previously had limited options after conventional therapies failed. Highlights from the Trials Patients receiving immunotherapy lived significantly longer than those on chemotherapy alone. Survival benefit was observed regardless of PD-L1 status, especially in recurrent cases after platinum-based treatment. Delays in disease progression gave patients more time with better quality of life. Immune checkpoint inhibitors helped reactivate the immune system's ability to target and destroy cervical cancer cells. Clinical Trial Treatment Type Median Overall Survival (OS) Disease Control Outcome Notes Phase III Study Immunotherapy + Chemo Up to 28.6 months vs 16.5 months Longer survival in all groups Strongest benefit in PD-L1+ patients Randomized Phase III Trial Immunotherapy (2nd-line) 11.7 months vs 8.5 months Benefit seen in all PD-L1 levels Works even after chemo failure * Both studies confirmed survival advantages without significantly higher severe side effects compared to chemotherapy alone. What This Means for Patients For women with recurrent, persistent, or metastatic cervical cancer, these results signal a new standard of care. Immunotherapy is not only more targeted than traditional therapies but also better tolerated, offering: A longer window of disease control (median progression-free survival extended); Improved quality of life with fewer systemic side effects; Hope for those who did not respond to chemotherapy or radiation. This also opens the door for future therapies involving antibody drug conjugates, personalized immune profiling, and combination treatments that utilize both the immune system and conventional medicine. Today, cervical cancer cohorts worldwide are benefiting from a more individualized, immune-driven approach that redefines what is possible after recurrence or metastasis. Who Benefits Most from Immunotherapy in Cervical Cancer? Immunotherapy is most effective for patients with PD-L1-positive, recurrent, or metastatic cervical cancer, particularly when standard treatments like chemotherapy or radiation therapy have failed, as previously mentioned. These patients often have limited options, and immunotherapy provides a targeted approach that can activate the immune system to attack tumor cells more effectively. Common Eligibility Criteria for Immunotherapy Patients who may benefit from immunotherapy typically meet one or more of the following criteria: PD-L1 expression ≥1% (as determined by tumor biopsy); Recurrent or metastatic cervical cancer following standard treatment; Persistent squamous cell carcinoma that does not respond to initial therapies; Evidence of T cell infiltration or active immune cell presence within the tumor; No contraindications for immune checkpoint blockade (e.g., autoimmune diseases). Histology Type Prevalence Response to Immunotherapy Squamous Cell Carcinoma ~80-90% Better overall immune response; more PD-L1 expression; strong T cell infiltration Adenocarcinoma ~10-20% Slightly lower PD-L1 expression; emerging data still promising Adenosquamous/Mixed <5% Limited clinical data; under investigation While both subtypes may benefit, squamous cell carcinoma tends to respond more favorably due to its immunogenicity and higher prevalence of immune markers like PD-L1. Why This Is Important Understanding which patients are most likely to respond helps oncologists personalize therapy, avoid unnecessary toxicity, and improve overall outcomes in metastatic cervical cancer patients. As clinical trials continue to evolve, biomarkers like PD-L1, tumor-infiltrating lymphocytes, and even genomic profiling are playing a larger role in guiding treatment selection. What Are the Current Limitations and Side Effects of Immunotherapy? While immunotherapy is an innovative option in cervical cancer treatment, it is not without limitations. Not all patients experience a positive immune response, and treatment can lead to side effects caused by overstimulation of the immune system. Main Limitations of Immunotherapy for Cervical Cancer Variable response rates: Only patients with specific tumor profiles (e.g., PD-L1-positive tumors or high T cell infiltration) tend to respond. Delayed response: Unlike chemotherapy, benefits may take weeks or months to appear. Immune hyperactivation: Some patients may develop autoimmune-like reactions when the immune system attacks healthy tissue. High costs: Immunotherapy is expensive, and coverage varies widely by country and provider. Limited access: Not all regions offer advanced immune-based therapies or diagnostic testing. Side Effect Type Description Frequency Colitis Inflammation of the colon causing diarrhea Moderate Thyroiditis/Hypothyroidism Immune attack on the thyroid Common Dermatitis or skin rash Immune-related skin inflammation Common Fatigue and joint pain General inflammatory response Mild to moderate Pneumonitis Lung inflammation (rare but serious) Rare Cleveland Clinic highlights that these side effects are often immune-related and differ from those of chemotherapy, which typically causes nausea, hair loss, and bone marrow suppression. Most immune-related reactions are manageable with corticosteroids or immunosuppressive agents when diagnosed early. Importance of Tumor Profiling and Biomarker Testing Before initiating immunotherapy, tumor profiling is crucial. Tests that assess PD-L1 expression, tumor mutational burden, and immune cell markers help determine whether a patient is a good candidate. This ensures that patients treated are those most likely to benefit from therapy while minimizing unnecessary risks. Why Are More Patients Going Abroad for Cervical Cancer Immunotherapy? Many cervical cancer patients choose to go abroad for immunotherapy because of faster access, broader treatment options, and advanced clinical expertise – especially in countries known for innovation in gynecologic oncology. In many parts of the world, patients face long wait times, outdated systemic therapies, or limited access to next-generation immune system-based treatments. This is especially critical for women with advanced or recurrent cervical cancer, where timely intervention can directly affect survival and quality of life. In contrast, specialized cancer centers in countries like Germany offer accelerated treatment pathways, advanced diagnostics, and access to experimental options not yet widely available elsewhere. Primary Reasons Patients Travel Abroad for Treatment Limited access at home: In some countries, immune checkpoint inhibitors and personalized immunotherapy are not yet standard care – or are cost-prohibitive without insurance support. Delays in diagnosis or therapy: Long waitlists for oncology consultations or biopsy testing can result in treatment delays that worsen outcomes. Patients who choose to treat cervical cancer abroad often report improved outcomes, better coordination, and more comprehensive care – especially when guided by experienced facilitators like Booking Health. From Research to Results: How Immunotherapy Extends Life Expectancy Recent clinical advances highlight the growing role of immunotherapy in improving life expectancy for patients with stage 4 cervical cancer. Immune checkpoint inhibitors and other immune-based treatments are showing encouraging results, particularly for recurrent, metastatic, and PD‑L1‑positive cervical cancers, where traditional chemotherapy offers limited benefit. By stimulating the body's own immune system to recognize and attack tumor cells, these therapies have been linked to longer survival and improved progression-free outcomes in international studies. Access to such innovative care remains uneven, prompting patients to seek specialized oncology centers abroad. Through coordination platforms such as Booking Health, individuals are able to connect with leading hospitals in Germany and other countries that offer advanced cervical cancer immunotherapy programs. These multidisciplinary approaches combine personalized treatment planning, modern diagnostics, and targeted immune modulation to address late‑stage disease. As immunotherapy research continues to expand, it represents a significant shift in the management of advanced cervical cancer, giving more women a realistic chance at extended survival and an improved quality of life. Key Takeaways: Immunotherapy's Impact on Advanced Cervical Cancer Immunotherapy offers hope for women with stage 4 cervical cancer, especially when other treatments have failed. It works by strengthening the immune system to recognize and eliminate cancer cells more effectively. Most effective in patients with PD-L1-positive, recurrent, metastatic, or invasive cervical cancer. Recent phase III clinical trials show longer survival and improved median progression-free survival compared to chemotherapy alone. Booking Health connects international patients with leading European hospitals that specialize in cervical cancer immunotherapy and personalized care. These breakthroughs represent a major advancement in the treatment of metastatic cervical cancer – delivering not only longer survival, but also a significantly improved quality of life. To explore your personalized treatment options, contact Booking Health today and take the next step toward advanced cervical cancer care. Side_Effects About Booking Health Booking Health™ is the international platform for rapid access to innovative treatments in the world's leading certified clinics. Our network features over 250 top-tier hospitals across the globe, all distinguished by the exceptional levels of medical accreditation and expertise. By arranging care with the help of Booking Health company, you benefit from comprehensive medical support based on the latest innovations and personalized coordination. We offer cost saving up to 70% compared to direct booking via clinics — all without compromising on quality. Choosing Booking Health means more than just acquiring access to innovative world-class therapy – it means saving valuable time knowing that every detail is handled by professionals. Headquartered in Bad Hönningen, Germany and officially registered in Düsseldorf under HRB 106466, Booking Health proudly consults patients from over 75 countries for over a decade, offering services in 11 languages. Press inquiries Booking Health Lena Hanten [email protected]